Home › Research › Treatments
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL et al.. JAMA, 2014-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Importance Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Design, setting, and participants The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013. Results Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures. Results from the mADCS-CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P = .01. Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam. Conclusions and relevance Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day.
What this study adds
Evidence grade: High
This is a trial of 186 participants. In a double-blind trial of 186 people with probable Alzheimer disease and agitation, all already receiving psychosocial support, 40% of those given citalopram showed moderate or marked improvement versus 26% on placebo, and caregiver distress also fell. It did not improve the NPI agitation subscale or daily activities, and the authors warn that cognitive and cardiac side effects "may limit its practical application" at 30 mg per day.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., et al. (2014). Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2014.93
Vancouver
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014. doi:10.1001/jama.2014.93. PMID: 24549548.
BibTeX
@article{porsteinsson2014-24549548,
author = {Porsteinsson, A. P. and Drye, L. T. and Pollock, B. G. and Devanand, D. P. and Frangakis, C. and Ismail, Z. and Marano, C. and Meinert, C. L. and others},
title = {{Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial}},
journal = {JAMA},
year = {2014},
doi = {10.1001/jama.2014.93},
pmid = {24549548},
url = {https://doi.org/10.1001/jama.2014.93}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Importance Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease.
- Design, setting, and participants The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013.
- Results Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures.
- Results from the mADCS-CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P = .01.
- Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam.
Why it matters
In a double-blind trial of 186 people with probable Alzheimer disease and agitation, all already receiving psychosocial support, 40% of those given citalopram showed moderate or marked improvement versus 26% on placebo, and caregiver distress also fell. It did not improve the NPI agitation subscale or daily activities, and the authors warn that cognitive and cardiac side effects "may limit its practical application" at 30 mg per day.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants186
- Evidence strengthHigh
How this study scored 82/100
Published in a top-tier journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 186 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 574 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 41.0 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 6 / 6 | Cited 43.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 22 other studies in this library |
| Still being cited | 3 / 4 | Cited 109 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Constantine George Lyketsos: h-index 130 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24549548) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 82 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
22 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.